Clinical Trials Logo

Cocaine Dependence clinical trials

View clinical trials related to Cocaine Dependence.

Filter by:

NCT ID: NCT02994875 Completed - Cocaine Dependence Clinical Trials

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

Start date: May 2016
Phase: Early Phase 1
Study type: Interventional

The objective of this research is to identify the functional neural mechanisms (as assessed using fMRI) of short-term N-acetylcysteine (NAC) administration among methadone-maintained individuals with cocaine dependence.

NCT ID: NCT02935101 Terminated - Cocaine Dependence Clinical Trials

Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants

Goliath
Start date: October 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether prednisolone lowers intensity and frequency of craving in heroin-addicted subjects undertaking a detoxification of cocaine and/or heroin.

NCT ID: NCT02927236 Recruiting - Cocaine Dependence Clinical Trials

Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use

Start date: February 13, 2017
Phase: Phase 4
Study type: Interventional

Background: More effective treatments for people with cocaine use disorder are needed. Researchers want to understand the parts of the brain involved in the disorder. Transcranial magnetic stimulation (TMS) stimulates parts of the brain. A form of TMS called intermittent theta-burst stimulation (iTBS) may help reduce cocaine use. Researchers want to learn how the brain might change with treatment. Objectives: To test if iTBS can reduce cocaine use. Also, to learn how cocaine changes the heart and the brain. Eligibility: Healthy, right-handed adults ages 18-60 who do or do not have cocaine use disorder. Design: Participants will be screened with: - Questionnaires - Medical history - Physical exam - Blood and urine tests - Alcohol breath tests In the pilot study, 10 participants with cocaine use disorder will have 10 treatment days over 2 weeks. Half will be inpatient and half will be outpatient. They will have 2 follow-up visits. Treatment includes: - iTBS: A coil is placed on the head. A brief electrical current passes through the coil. They view cocaine-related images during each session. Sessions are videotaped. - Repeat of screening tests - In the main study, participants will be randomly assigned to have either real or fake iTBS. - Participants with cocaine use disorder will join an incentive program to quit. - Participants will have 39 visits over 6 months. These include: - Repeat of screening tests - MRIs at 5 visits: Participants lie on a table that slides into a cylinder that takes pictures of the brain. They respond to images while in the scanner. - iTBS at 10 visits (5 days a week for 2 weeks) Participants will be contacted throughout the study to discuss iTBS treatment and drug use.

NCT ID: NCT02774954 Completed - HIV Clinical Trials

Change the Cycle: An RCT to Prevent Injection Initiation

CTC
Start date: June 2016
Phase: N/A
Study type: Interventional

The study will test the efficacy of a hour long, one-on-one, active listening counseling session (called Change the Cycle or CTC) aimed at reducing behaviors among active people who inject drugs (PWID) that research has found to facilitate uptake of injection drug use among non-injectors. The study will involve ~1,100 PWID who will be randomized to CTC or an equal attention control intervention on improving nutrition. Participants will be recruited in Los Angeles and San Francisco, California and followed up at 6 and 12 months to determine changes in direct and indirect facilitation of injection initiation among non-injectors.

NCT ID: NCT02596022 Completed - Cocaine Dependence Clinical Trials

The Effect of Glutamatergic Modulation on Cocaine Self-administration

Start date: June 2013
Phase: Phase 2
Study type: Interventional

Repeated drug consumption may progress to problematic use by triggering neuroplastic adaptations that attenuate sensitivity to natural rewards while increasing reactivity to craving and drug cues. Converging evidence suggests that glutamate modulation may work to correct these adaptations and rapidly restore motivation for delayed non-drug rewards relative to immediate drug use. Using an established laboratory model aimed at evaluating behavioral shifts in the salience of cocaine now vs. money later, the investigators will test the effect of CI-581a on cocaine self-administration as compared to the active control.

NCT ID: NCT02563769 Completed - Cocaine Dependence Clinical Trials

Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

Start date: October 24, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine if it is safe to use the study drug, clavulanic acid, in combination with cocaine. In this study, subjects will receive intravenous (i.v.) cocaine and the study drug, clavulanic acid. The safety of clavulanic acid is being studied so future studies can be done to find out if this drug is helpful in treating cocaine dependence. Currently, there is no available medication treatment for cocaine dependence.

NCT ID: NCT02559167 Completed - Cocaine Dependence Clinical Trials

Cannabidiol and Cocaine Craving/Dependence

CBD
Start date: July 1, 2016
Phase: Phase 2
Study type: Interventional

In this study, the investigators seek to evaluate the effects of cannabidiol (CBD) on cocaine craving and relapse. Cocaine addiction is characterized by compulsive substance use and repetitive urges to consume the drug even after a sustained period of abstinence. While substance use remains the most obvious direct outcome of addiction, there is a growing interest in other core symptoms of this disorder. Craving has become a subject of great interest as it is a reliable intermediate phenotype of cocaine relapse and a distressing symptom of addiction associated with suffering. Indeed, even after a period of abstinence, cocaine-dependent individuals remain vulnerable to stress and other craving-inducing stimuli, which, in turn, lead to intense physiological responses and various negative feelings such as anger and sadness. Real-time daily monitoring of craving and drug use has shown that craving predicts cocaine relapse among cocaine-dependent individuals. In sum, working toward improving the treatment of craving could not only help prevent relapse, but also reduce patient distress on emotional, cognitive, and physiological levels. In the past decades, significant scientific efforts have been deployed toward the development of innovative strategies to beat cocaine addiction, but with partial success thus far. Psychosocial approaches have been widely used to help cocaine-dependent patients achieve better outcomes after drug cessation, but literature indicates that these strategies alone are at times insufficient to induce significant behavioural changes or a reduction in rates of drug consumption. Unlike other types of addiction, such as opioid and alcohol, no pharmacological treatment has yet been found to be truly effective in relieving cocaine-cessation symptoms like craving and anxiety or to prevent relapse. CBD is a natural cannabinoid with a favourable tolerability profile and discrete neurobiological actions that are linked to neural circuits closely involved in addiction disorders. Addiction to cocaine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Our hypothesis is that CBD a cannabinoid known for its broad spectrum properties is an interesting pharmacological contender to decrease cocaine craving and treat cocaine addiction. Previous studies conducted in animals and humans confirm that CBD is a very safe and tolerable medication.

NCT ID: NCT02538744 Completed - Cocaine Dependence Clinical Trials

Complementary Combination Therapy for Cocaine Dependence

Start date: August 2015
Phase: Phase 1
Study type: Interventional

The investigators will assess the impact of treatment with doxazosin and modafinil, alone and in combination, on the subjective and reinforcing effects of cocaine in non-treatment-seeking, cocaine-dependent volunteers. The investigators will use a hybrid design in which participants will be randomized into two groups: placebo and doxazosin 8 mg/d. They will remain in their assigned group for the duration of the study. After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0, 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).

NCT ID: NCT02455479 Recruiting - Cocaine Dependence Clinical Trials

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

Start date: June 26, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking "immunity" to prevent the effects of cocaine on the brain.

NCT ID: NCT02416050 Completed - Cocaine Dependence Clinical Trials

Predicting Relapse After Cocaine Inpatient Cessation

QUIT-COC
Start date: February 3, 2015
Phase:
Study type: Observational

Can brain MRI at entry of cocaine inpatient cessation attempt predict relapse during a three month follow-up ? Hypothesis : White matter losses in the prefrontal cortex are associated with relapse to cocaine use.